sales@ambeed.com

Structure Search

List Search MOL Search Structure Search

Hello, Sign in

Home Cart 0 Sign in

X

[ CAS No. 62718-28-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 62718-28-9

Chemical Structure| 62718-28-9

Chemical Structure| 62718-28-9

Structure of 62718-28-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 62718-28-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 62718-28-9 ]

SDS Specification

Alternatived Products of [ 62718-28-9 ]

Product Details of [ 62718-28-9 ]

CAS No. :	62718-28-9	MDL No. :	MFCD06658488
Formula :	C₇H₁₄N₂O	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	BTVJTKWOCSGJDQ-UHFFFAOYSA-N
M.W :	142.20	Pubchem ID :	339011
Synonyms :

Calculated chemistry of [ 62718-28-9 ]

Physicochemical Properties

Num. heavy atoms :	10
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.86
Num. rotatable bonds :	1
Num. H-bond acceptors :	2.0
Num. H-bond donors :	1.0
Molar Refractivity :	43.37
TPSA :	46.33 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.43 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.45
Log Po/w (XLOGP3) :	-0.37
Log Po/w (WLOGP) :	-0.57
Log Po/w (MLOGP) :	-0.05
Log Po/w (SILICOS-IT) :	0.07
Consensus Log Po/w :	0.11

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-0.42
Solubility :	53.7 mg/ml ; 0.378 mol/l
Class :	Very soluble
Log S (Ali) :	-0.14
Solubility :	103.0 mg/ml ; 0.724 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-0.33
Solubility :	67.1 mg/ml ; 0.472 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.12

Safety of [ 62718-28-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 62718-28-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 62718-28-9 ]
Downstream synthetic route of [ 62718-28-9 ]

[ 62718-28-9 ] Synthesis Path-Upstream 1~9

1
[ 39546-32-2 ]
[ 50-00-0 ]
[ 62718-28-9 ]

Yield	Reaction Conditions	Operation in experiment
64%	With hydrogen In water at 25℃; for 43 h;	ISONIPECOTAMIDE (10G, 78. Ommoles) was dissolved in distilled water (100ML) and 37percent aqueous formaldehyde (7.6mL, equivalent to 2. 81g HCHO, 93. 6MMOLES) was added. Wet 10percent Pd-C (8 spoon spatulas) was added under argon and the mixture was hydrogenated at 25 C and 50psi FOR 43H. The catalyst was filtered off through Celite and the latter was washed with water and methanol. The combined filtrates were evaporated to dryness and the residue was chromatographed on a silica gel column (60x5cm) using 8percent-10percent-20percent (10percent CONC. ammonium hydroxide in METHANOL)-DICHLOROMETHANE as the eluant to give 1-methylisonipecotamide (7.15g, 64percent): FABMS: m/z 143.1 (MH+) ; HRFABMS: m/z 143.1184 (MH+). CALCD. FORC7H15N2O : m/z 143.1184 ; No.H (d6- DMSO) 1.50/1. 57 (4H, m, CH2), 1.76/1. 94 (4H, m, CH2), 2.10 (3H, s,-NCH3), 2.72 (1H, m, CH) and 6.68/7. 18 ppm (2H, M, CONH2); 8c (D6-DMSO) CH3 : 41.2 ; CH2: 28.5, 28.5, 54.9, 54.9 ; CH: 46.2 ; C: 176.7.

Reference： [1] Journal of Medicinal Chemistry, 2003, vol. 46, # 7, p. 1116 - 1119
[2] Patent: WO2004/22561, 2004, A1, . Location in patent: Page 110
[3] Journal of Medicinal Chemistry, 2005, vol. 48, # 24, p. 7520 - 7534
[4] Helvetica Chimica Acta, 1954, vol. 37, p. 1672,1676

2
[ 1690-75-1 ]
[ 62718-28-9 ]

Reference： [1] Helvetica Chimica Acta, 1954, vol. 37, p. 1672,1676

3
[ 2459-09-8 ]
[ 62718-28-9 ]

Reference： [1] Helvetica Chimica Acta, 1954, vol. 37, p. 1672,1676

4
[ 1453-82-3 ]
[ 62718-28-9 ]

Reference： [1] Helvetica Chimica Acta, 1954, vol. 37, p. 1672,1676

5
[ 7630-02-6 ]
[ 62718-28-9 ]

Reference： [1] Helvetica Chimica Acta, 1954, vol. 37, p. 1672,1676

6
[ 1453-82-3 ]
[ 74-88-4 ]
[ 62718-28-9 ]

Reference： [1] Yakugaku Zasshi, 1956, vol. 76, p. 968[2] Chem.Abstr., 1957, p. 2771

7
[ 62718-28-9 ]
[ 41838-46-4 ]

Reference： [1] Yakugaku Zasshi, 1956, vol. 76, p. 968[2] Chem.Abstr., 1957, p. 2771

8
[ 62718-28-9 ]
[ 7149-42-0 ]

Yield	Reaction Conditions	Operation in experiment
11%	With lithium aluminium tetrahydride In tetrahydrofuran at 0 - 66℃; for 25.5 h;	1-METHYLISONIPECOTAMIDE (6.75g, 47. 5MMOLES) (PREPARED as described in Preparative Example 245, Step A above) was dissolved in anhydrous THF (350mL) and the resulting mixture was added in portions to a stirred slurry of lithium aluminum hydride (1.8g, 47. 5mmoles) in anhydrous THF (100ML) at 0 C under nitrogen. The mixture was stirred at 0 C for 30min and then heated at 66 C for 25h under nitrogen. Distilled water (1.88mL) was added dropwise to the stirred mixture at 0 C, followed by 20percent aqueous sodium hydroxide (1.42mL) and then distilled water (6.75mL) and the mixture was stirred for 15min. The mixture was filtered and the solids were washed with THF and dichloromethane. The combined filtrates were evaporated to dryness and chromatographed on a silica gel column (30x5cm) using 15percent-20percent (10percent CONC. ammonium hydroxide in METHANOL)-DICHLOROMETHANE as the eluant to give 4-(aminomethyl)-1- methylpiperidine (0.678g, 11percent) : FABMS: m/z 129.1 (MH+) ; HRFABMS: m/z 129.1389 (MH+). Calcd. FOR C7HL7N2 : m/z 129.1392 ; aH (d6-DMSO) : 2.08ppm (3H, S,-NCH3) ; 8C (D6-DMSO) : CH3: under DMSO peaks; CH2: 29.6, 29.6, 46.7, 55.2, 55.2 ; CH: 46.2.

Reference： [1] Journal of Medicinal Chemistry, 2003, vol. 46, # 7, p. 1116 - 1119
[2] Patent: WO2004/22561, 2004, A1, . Location in patent: Page 110-11

9
[ 62718-28-9 ]
[ 26458-78-6 ]

Reference： [1] Helvetica Chimica Acta, 1954, vol. 37, p. 1672,1676

[ 62718-28-9 ] Synthesis Path-Downstream 1~34

1
[ 39546-32-2 ]
[ 50-00-0 ]
[ 62718-28-9 ]

Yield	Reaction Conditions	Operation in experiment
64%	With hydrogen;palladium; In water; at 25℃; under 2585.81 Torr; for 43h;	ISONIPECOTAMIDE (10G, 78. Ommoles) was dissolved in distilled water (100ML) and 37% aqueous formaldehyde (7.6mL, equivalent to 2. 81g HCHO, 93. 6MMOLES) was added. Wet 10% Pd-C (8 spoon spatulas) was added under argon and the mixture was hydrogenated at 25 C and 50psi FOR 43H. The catalyst was filtered off through Celite and the latter was washed with water and methanol. The combined filtrates were evaporated to dryness and the residue was chromatographed on a silica gel column (60x5cm) using 8%-10%-20% (10% CONC. ammonium hydroxide in METHANOL)-DICHLOROMETHANE as the eluant to give 1-methylisonipecotamide (7.15g, 64%): FABMS: m/z 143.1 (MH+) ; HRFABMS: m/z 143.1184 (MH+). CALCD. FORC7H15N2O : m/z 143.1184 ; No.H (d6- DMSO) 1.50/1. 57 (4H, m, CH2), 1.76/1. 94 (4H, m, CH2), 2.10 (3H, s,-NCH3), 2.72 (1H, m, CH) and 6.68/7. 18 ppm (2H, M, CONH2); 8c (D6-DMSO) CH3 : 41.2 ; CH2: 28.5, 28.5, 54.9, 54.9 ; CH: 46.2 ; C: 176.7.

Reference： [1]Journal of Medicinal Chemistry,2003,vol. 46,p. 1116 - 1119
[2]Patent: WO2004/22561,2004,A1 .Location in patent: Page 110
[3]Journal of Medicinal Chemistry,2005,vol. 48,p. 7520 - 7534
[4]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

2
[ 1690-75-1 ]
[ 62718-28-9 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

3
[ 1453-82-3 ]
[ 74-88-4 ]
[ 62718-28-9 ]

Reference： [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1956,vol. 76,p. 968
Chem.Abstr.,1957,p. 2771

4
[ 62718-28-9 ]
[ 41838-46-4 ]

Reference： [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1956,vol. 76,p. 968
Chem.Abstr.,1957,p. 2771

5
[ 62718-28-9 ]
[ 20691-92-3 ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 7520 - 7534
[2]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1954,vol. 74,p. 714
Chem.Abstr.,1955,p. 11647
[3]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

7
[ 62718-28-9 ]
[ 7149-42-0 ]

Yield	Reaction Conditions	Operation in experiment
11%	With lithium aluminium tetrahydride; In tetrahydrofuran; at 0 - 66℃; for 25.5h;	1-METHYLISONIPECOTAMIDE (6.75g, 47. 5MMOLES) (PREPARED as described in Preparative Example 245, Step A above) was dissolved in anhydrous THF (350mL) and the resulting mixture was added in portions to a stirred slurry of lithium aluminum hydride (1.8g, 47. 5mmoles) in anhydrous THF (100ML) at 0 C under nitrogen. The mixture was stirred at 0 C for 30min and then heated at 66 C for 25h under nitrogen. Distilled water (1.88mL) was added dropwise to the stirred mixture at 0 C, followed by 20% aqueous sodium hydroxide (1.42mL) and then distilled water (6.75mL) and the mixture was stirred for 15min. The mixture was filtered and the solids were washed with THF and dichloromethane. The combined filtrates were evaporated to dryness and chromatographed on a silica gel column (30x5cm) using 15%-20% (10% CONC. ammonium hydroxide in METHANOL)-DICHLOROMETHANE as the eluant to give 4-(aminomethyl)-1- methylpiperidine (0.678g, 11%) : FABMS: m/z 129.1 (MH+) ; HRFABMS: m/z 129.1389 (MH+). Calcd. FOR C7HL7N2 : m/z 129.1392 ; aH (d6-DMSO) : 2.08ppm (3H, S,-NCH3) ; 8C (D6-DMSO) : CH3: under DMSO peaks; CH2: 29.6, 29.6, 46.7, 55.2, 55.2 ; CH: 46.2.

Reference： [1]Journal of Medicinal Chemistry,2003,vol. 46,p. 1116 - 1119
[2]Patent: WO2004/22561,2004,A1 .Location in patent: Page 110-11

8
[ 62718-28-9 ]
1,4-dimethyl-piperidine-4-carbothioic acid amide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 7520 - 7534

9
[ 62718-28-9 ]
[ 1027041-17-3 ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 7520 - 7534

10
[ 62718-28-9 ]
<i>N</i>-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-[2-(1,4-dimethyl-piperidin-4-yl)-thiazol-4-yl]-benzamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 7520 - 7534

11
[ 62718-28-9 ]
[ 62718-29-0 ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 7520 - 7534

12
[ 62718-28-9 ]
5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (1-methyl-piperidin-4-ylmethyl)-amide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2003,vol. 46,p. 1116 - 1119

13
[ 2459-09-8 ]
[ 62718-28-9 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

14
[ 1453-82-3 ]
[ 62718-28-9 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

15
[ 62718-28-9 ]
[ 26458-78-6 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

16
[ 62718-28-9 ]
1-methyl-4-propyl-piperidine-4-carbonitrile [ No CAS ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

17
[ 62718-28-9 ]
8-methyl-2-oxa-8-aza-spiro[4.5]decan-1-one [ No CAS ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

18
[ 62718-28-9 ]
[ 115291-14-0 ]

Reference： [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1956,vol. 76,p. 968
Chem.Abstr.,1957,p. 2771

19
[ 62718-28-9 ]
[ 106594-21-2 ]

Reference： [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1956,vol. 76,p. 968
Chem.Abstr.,1957,p. 2771

20
[ 62718-28-9 ]
[ 92040-00-1 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676
[2]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

21
[ 62718-28-9 ]
[ 20691-91-2 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

22
[ 62718-28-9 ]
[ 65345-83-7 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

23
[ 62718-28-9 ]
[ 112864-70-7 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

24
[ 62718-28-9 ]
[ 55022-88-3 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

25
[ 7630-02-6 ]
[ 62718-28-9 ]

Reference： [1]Helvetica Chimica Acta,1954,vol. 37,p. 1672,1676

26
[ 1189852-16-1 ]
[ 62718-28-9 ]
[ 76-05-1 ]
1-(5-(4-(2-hydroxypropan-2-yl)benzamido)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl)-N-methylpiperidine-4-carboxamide trifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
24%		N-(7-chloro-2-methylpyrazolo[ 1 ,5-a]pyrimidin-5-yl)-4-(2-hydroxypropan-2- yl)benzamide (2F, 0.05g, 1.0 equivalent) and <strong>[62718-28-9]N-methylpiperidine-4-carboxamide</strong> (2.0 equivalents) in DMF (0.1M) was heated to 100 0C for 6h. Then another 2.0 equivalents of N- methylpiperidine-4-carboxamide was added and heated to 100 0C for 4h. Then the solvent was removed in vacuo and the crude mixture was purified by preparatory HPLC (20-35% ACN/water, TFA mode) to afford the TFA salt of the titled compound, which was further purified by MeOH and then EtOAc wash and filtered to afford the titled compound (24%) as a white solid. 1H NMR (400 MHz, DMSO-J6) delta ppm 1.45 (s, 6 H) 1.70 - 1.90 (m, 4 H) 2.37 (s, 3 H) 2.39 - 2.48 (m, 1 H) 2.59 (d, J=4.80 Hz, 3 H) 3.08 (t, J=I 1.24 Hz, 2 H) 4.46 (d, J=12.38 Hz, 2 <n="322"/>PATENT ASKl -5001 -WOH) 6.15 (s, 1 H) 7.33 (s, 1 H) 7.56 - 7.63 (m, 2 H) 7.83 (q, J=4.46 Hz, 1 H) 7.95 - 8.03 (m, 2 H) 10.83 (s, 1 H); ESI-MS: m/z 451.2 (M+H)+.

Reference： [1]Patent: WO2009/123986,2009,A1 .Location in patent: Page/Page column 320-321

27
[ 19172-47-5 ]
[ 62718-28-9 ]
[ 88654-17-5 ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran; methanol; conc. aq. NH4OH; 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran; toluene;	Intermediate 20: step a 1-Methylpiperidine-4-carbothioamide To a suspension of <strong>[62718-28-9]1-methylpiperidine-4-carboxamide</strong> (3.97 g, 27.9 mmol, Amfinecom) in a mixture of toluene (70 mL) and THF (30 mL) was added Lawesson's reagent (6.78 g, 16.8 mmol). The resulting light yellow suspension was heated at reflux for 22 h. The reaction mixture was diluted with DCM and MeOH and was concentrated onto silica gel for purification by column chromatography (Silica gel, 1-8% MeOH in 98:2 DCM:conc. aq. NH4OH, water layer removed in a separatory funnel), affording the title compound as a yellow solid.

Reference： [1]Patent: US2012/302573,2012,A1

28
[ 62718-28-9 ]
[ 1377582-69-8 ]

Reference： [1]Patent: US2012/129842,2012,A1
[2]Patent: US2012/302573,2012,A1

29
[ 62718-28-9 ]
2-bromo-1-(4-methyl-2-(1-methylpiperidin-4-yl)thiazol-5-yl)ethanone.HBr [ No CAS ]

Reference： [1]Patent: US2012/302573,2012,A1

30
[ 62718-28-9 ]
[ 88654-17-5 ]

Yield	Reaction Conditions	Operation in experiment
	With Lawessons reagent; In tetrahydrofuran; toluene; for 22h;Reflux;	Intermediate 68: Step a 1-Methylpiperidine-4-carbothioamide To a suspension of <strong>[62718-28-9]1-methylpiperidine-4-carboxamide</strong> (3.97 g, 27.9 mmol, Amfinecom) in a mixture of toluene (70 mL) and THF (30 mL) was added Lawesson's reagent (6.78 g, 16.8 mmol). The resulting light yellow suspension was heated at reflux for 22 h. The reaction mixture was diluted with DCM and MeOH and was concentrated onto silica gel for purification by column chromatography (Silica gel, 1-8% MeOH in 98:2 DCM:conc. aq. NH4OH, water layer removed in a separatory funnel), affording the title compound as a yellow solid.

Reference： [1]Patent: US2012/129842,2012,A1 .Location in patent: Page/Page column 67

31
[ 62718-28-9 ]
2-bromo-1-(4-methyl-2-(1-methylpiperidin-4-yl)thiazol-5-yl)ethanone hydrobromide [ No CAS ]

Reference： [1]Patent: US2012/129842,2012,A1

32
4-((2-(butylamino)-5-(5-chloropyridin-2-yl)pyrimidine-4-yl)amino)cyclohexanol [ No CAS ]
[ 62718-28-9 ]
N-(6-(2-(butylamino)-4-((trans-4-hydroxycyclohexyl)amino)pyrimidin-5-yl)pyridin-3-yl)-1-methylpiperidine-4-carboxamide hydrochloride [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2013,vol. 56,p. 9683 - 9692

33
3-(tert-butyl)-1-(5-((2-chloropyridin-4-yl)oxy)-6-methylpyridin-2-yl)-1H-1,2,4-triazol-5(4H)-one [ No CAS ]
[ 62718-28-9 ]
N-(4-((6-(3-(tert-butyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-methylpyridin-3-yl)oxy)pyridin-2-yl)-1-methylpiperidine-4-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
16.5%	With 1,1'-bis-(diphenylphosphino)ferrocene; tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; In 1,4-dioxane; at 100℃;Inert atmosphere;	A round bottom flask was charged with Example A3 (0.189 g, 0.525 mmol) in dioxane (5 mL) and sparged with Ar under sonication for 20 minutes after which 1- methylpiperidine-4-carboxamide (0.149 g, 1.051 mmol), CS2CO3 (0.342 g, 1.051 mmol), and DPPF (0.029 g, 0.053 mmol) was added and the mixture sparged with Ar under sonication for 15 minutes. Pd2(dba)3 (0.024 g, 0.026 mmol) was added and the mixture was sparged with Ar under sonication for 15 minutes. The reaction was then heated to 100 C under Ar and stirred overnight. The reaction mixture was cooled to RT, sparged with Ar under sonication and added Pd2(dba)3 (0.024 g, 0.026 mmol), DPPF (0.029 g, 0.053 mmol), sparged with Ar under sonication and then heated to 100 C and stirred overnight. The reaction mixture was cooled to RT, sparged with Ar under sonication and added Pd2(dba)3 (0.024 g, 0.026 mmol), DPPF (0.029 g, 0.053 mmol), sparged with Ar under sonication and then heated to 100 C and stirred overnight. The reaction mixture was cooled to RT, diluted with EtOAc and filtered through diatomaceous earth and washed with EtOAc. The filtrates were concentrated to dryness to afford a brown solid. The crude product was subject to reverse-phase silica gel chromatography (10% - 45% MeCN/water, 0.1% TFA). The appropriate fractions were collected, concentrated and stirred with EtOAc and sat'd NaHC03. The aqueous layer was back-extracted with EtOAc (3x), the organic phases combined, dried (Na2S04) and concentrated to dryness to afford a white solid. The product was suspended in MeCN/H20, frozen and lyopholized overnight to furnish N-(4- ((6-(3-(tert-butyl)-5-oxo-4,5-dihydro- 1H- 1 ,2,4-triazol- 1 -yl)-2-methylpyridin-3-yl)oxy)pyridin-2- yl)-l-methylpiperidine-4-carboxamide an off white solid. (0.0428 g, 16.5%). ' l NMR (400 MHz, OMSO-d6: delta 1 1.98 (br s, 1 H), 10.52 (s, 1 H), 8.19 (d, J = 5.7 Hz, 1 H), 7.86 (d, J = 8.8 Hz, 1 H), 7.69 (d, J = 8.8 Hz, 1 H), 7.58 (d, J = 2.4 Hz, 1 H), 6.69 (dd, J = 5.7, 2.4 Hz, 1 H), 2.81 - 2.71 (m, 2 H), 2.41 -2.33 (m, 1 H), 2.29 (s, 3 H), 2.13 (s, 3 H), 1.87-1.76 (m, 2 H), 1.71 -1.62 (m, 2 H), 1.56-1.47 (m, 2 H), 1.27 (s, 9 H); MS (ESI) m/z: 466.3 (M+H+).

Reference： [1]Patent: WO2014/145023,2014,A1 .Location in patent: Paragraph 0403

34
[ 1225278-66-9 ]
[ 62718-28-9 ]
1-methyl-N-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)piperidine-4-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
56%	With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; XPhos; In 1,4-dioxane; at 90℃;Inert atmosphere;	Example A8 A mixture of Example A1 (0.25 g, 0.994 mmol), Cs2CO3 (0.486 g, 1.490 mmol), <strong>[62718-28-9]1-methylpiperidine-4-carboxamide</strong> (0.155 g, 1.093 mmol), and X-phos (0.024 g, 0.050 mmol) in dioxane (5 mL) was sparged with Ar, treated with Pd2(dba)3 (0.045 g, 0.050 mmol) and heated at 90 C. overnight. Additional X-phos (17 mg) and Pd2(dba)3 (30 mg) were added and the mixture heated at 90 C. for 7 h. The mixture was cooled to RT, treated with water and extracted with EtOAc (3*). The combined organics were dried over Na2SO4, concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to afford 1-methyl-N-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)piperidine-4-carboxamide (200 mg, 56%). MS (ESI) m/z: 358.2 (M+H+).

Reference： [1]Patent: US2014/275016,2014,A1 .Location in patent: Paragraph 0221

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 62718-28-9 ]

Amides

[ 39546-32-2 ]

Piperidine-4-carboxamide

Similarity: 0.93

[ 39674-99-2 ]

Piperidine-4-carboxamide hydrochloride

Similarity: 0.90

[ 4138-26-5 ]

Piperidine-3-carboxamide

Similarity: 0.87

[ 1903-69-1 ]

N-Methylpiperidine-4-carboxamide

Similarity: 0.87

[ 3768-43-2 ]

2-Methyl-5-pentanelactam

Similarity: 0.84

Amines

[ 39546-32-2 ]

Piperidine-4-carboxamide

Similarity: 0.93

[ 39674-99-2 ]

Piperidine-4-carboxamide hydrochloride

Similarity: 0.90

[ 4138-26-5 ]

Piperidine-3-carboxamide

Similarity: 0.87

[ 1903-69-1 ]

N-Methylpiperidine-4-carboxamide

Similarity: 0.87

[ 51115-67-4 ]

2-Isopropyl-N,2,3-trimethylbutanamide

Similarity: 0.84

Related Parent Nucleus of
[ 62718-28-9 ]

Aliphatic Heterocycles

[ 39546-32-2 ]

Piperidine-4-carboxamide

Similarity: 0.93

[ 39674-99-2 ]

Piperidine-4-carboxamide hydrochloride

Similarity: 0.90

[ 4138-26-5 ]

Piperidine-3-carboxamide

Similarity: 0.87

[ 832710-65-3 ]

2,8-Diazaspiro[4.5]decan-1-one hydrochloride

Similarity: 0.82

[ 1147422-92-1 ]

2,7-Diazaspiro[3.5]nonan-1-one

Similarity: 0.82

Piperidines

[ 39546-32-2 ]

Piperidine-4-carboxamide

Similarity: 0.93

[ 39674-99-2 ]

Piperidine-4-carboxamide hydrochloride

Similarity: 0.90

[ 4138-26-5 ]

Piperidine-3-carboxamide

Similarity: 0.87

[ 1903-69-1 ]

N-Methylpiperidine-4-carboxamide

Similarity: 0.87

[ 3768-43-2 ]

2-Methyl-5-pentanelactam

Similarity: 0.84

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Ghs Hazard Statements

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere